Phase II trial with carboplatin and bendamustine in patients with extensive stage small-cell lung cancer

Journal of Thoracic Oncology

Volumn 2, Issue 4, 2007, Pages 312-316

  Köster, Wolf ^a   Heider, Andrea ^b   Niederle, Norbert ^b   Wilke, Hansjochen ^a   Stamatis, Georgios ^c   Fischer, Jürgen R ^d   Koch, Jens A ^a   Stahl, Michael ^a  

^a KLINIKEN ESSEN MITTE   (Germany)

^b KLINIKUM LEVERKUSEN   (Germany)

^c RUHRLANDKLINIK   (Germany)

^d Klinik Lowenstein   (Germany)

Author keywords

Chemotherapy; Extensive disease; Small cell lung cancer

Indexed keywords

BENDAMUSTINE; CARBOPLATIN; CORTICOSTEROID; METOCLOPRAMIDE; SEROTONIN 3 ANTAGONIST; ANTINEOPLASTIC AGENT; CHLORMETHINE DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HUMAN; INFECTION; LEUKOPENIA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION; CANCER STAGING; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; PATHOLOGY; PATIENT SELECTION; PROBABILITY; RISK ASSESSMENT;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; NITROGEN MUSTARD COMPOUNDS; PATIENT SELECTION; PROBABILITY; RISK ASSESSMENT;

EID: 34247863880     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01.JTO.0000263714.46449.4c     Document Type: Article

References (35)

1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe 2004. Ann Oncol 2005;16:481-488.
2. Chute JP, Chen T, Feigal E, et al. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999;17:1794-1801.
3. Reck M, Niederle N, Thomas M, et al. Erstlinientherapie des kleinzelligen Bronchialkarzinoms (SCLC). Onkologe 2005;11:722-729.
4. Griesinger F, Overbeck T, Niederle N, et al. Zweitlinientherapie des kleinzelligen Bronchialkarzinoms (SCLC). Onkologe 2005;11:730-740.
5. Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005;366:1385-1396.
6. Strumberg D, Harstrick A, Doll K, et al. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 1996;7:415-421.
7. Niemeyer C, Bailey B, Reiffert FJ, et al. SDX-105 (Bendamustine) is a clinically active chemotherapeutic agent with a distinct mechanism of action. Proc Am Assoc Cancer Res 2004;45, abstract 1129.
8. Leoni LM, Bailey B, Reiffert J, Niemeyer C, et al. In vitro and ex vivo activity of SDX-105 (bendamustine) in drug-resistant lymphoma cells. Proc Am Assoc Cancer Res 2004;45, abstract 1215.
9. Heider A, Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. Anticancer Drugs 2001;12:725-729.
10. Rummel MJ, Mitrou PS, Hoelzer D. Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives. Semin Oncol 2002;29:27-32.
11. Cohen P, Cheson B, Friedberg J, et al The novel alkylator, Trenada™ (bendamustine HCl), is active in both rituximab-refractory and rituximab-sensitive relapsed indolent NHL with acceptable toxicity. Proc Am Soc Clin Oncol 2005;23:(Suppl):576s, abstract 656.
12. Borchmann P, Schnell R, Diehl V, et al. New drugs in the treatment of Hodgkin's disease. Ann Oncol 1998;9:(Suppl 5):S103-S108.
13. Avaido M, Schulte K, Henze LM, et al. Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives. Semin Oncol 2002;29(Suppl 13):S19-S22.
14. Knauf WU, Lissitchkov T, Herbrecht R, et al. Bendamustine versus chlorambucil in treatment-naïve B-CLL patients. Blood 2004;104:11:287b, abstract 4817.
15. Ponisch W, Mitrou PS, Merkle K, et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 2006;132:204-212.
16. Pönisch W, Niederwieser D. Bendamustine in the treatment of multiple myeloma: results and future perspectives. Semin Oncol. 2002;29:(Suppl 13):S23-S26.
17. Köster W, Stamatis G, Heider A, et al. Carboplatin in combination with bendamustine in previously untreated patients with extensive-stage small cell lung cancer (SCLC). Clin Drug Invest 2004;24:611-618.
18. Reck M, Haering B, Koschel G, et al. Chemotherapie des fortgeschrittenen nicht-kleinzelligen und kleinzelligen Bronchialkarzinoms mit Bendamustin - Eine Phase II Studie. Pneumologie 1998;52:571-574.
19. Höffken K, Merkle K, Schönfelder M, et al. Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study. J Cancer Res Clin Oncol 1998;124:627-632.
20. Zulkowski K, Kath R, Semrou R, et al. Regression of brain metastases from breast carcinoma after chemotherapy with bendamustine. J Cancer Res Clin Oncol 2002;128:111-113.
21. von Minckwitz G, Chernozemsky I, Sirakova L et al. Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. Anticancer Drugs 2005;16:871-877.
22. Kollmannsberger C, Gerl A, Scheuler N, et al. Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer. Anticancer Drugs 2000;11:535-539.
23. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982;38:143-151.
24. Sundstrom S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results form a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002;20:4618-4620.
25. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91.
26. Eckardt JR, von Pawel J, Manikhas G, et al. Comparable activity with oral topotecan/cisplatin and iv etoposide/cisplatin as treatment for chemotherapy-naïve patients with extensive disease small cell lung cancer: final results of a randomized phase III trial. Proc Am Soc Clin Oncol 2005;23:622s(LBA 7004).
27. Takigawa N, Fujiwara K, Ueoka H, et al. Fractionated administration of irinotecan and cisplatin for treatment for extensive-disease small-cell lung cancer: a phase II study. Anticancer Res 2003;23:557-560.
28. Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase iii trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small cell-lung cancer. J Clin Oncol 24:2038-2043.
29. Quoix E, Breton JL, Gervais R, et al. A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer. Lung Cancer 2005;49:253-261.
30. Seifart U, Jensen K, Ukena J, et al. Randomized phase II study comparing topotecan/cisplatin administration for 5 days versus 3 days in the treatment of extensive stage small cell lung cancer. Lung Cancer 2005;48:415-422.
31. Neubauer M, Heaven R, Olivares J, et al. Results of a phase II study of carboplatin plus gemcitabine in patients with untreated extensive small cell lung cancer. Lung Cancer 2004;46:369-375.
32. Neubauer M, Schwartz J, Caracandas J, et al. Results of a phase II study of weekly paclitaxel plus carboplatin in patients with extensive small-cell lung cancer with Eastern Cooperative Oncology Group performance status of 2, or age > or = 70 years. J Clin Oncol 2004;22:1872-1877.
33. Vieitez JM, Valladares M, Garcia M, et al. Phase II study of carboplatin and 1h-intravenous etoposide and paclitaxel in a novel sequence as first-line treatment of patients with small-cell lung cancer. Lung Cancer 2003;39:77-84.
34. Socinsky MA, Neubauer MA, Olivares J, et al. Phase II trial of paclitaxel, ifosfamide, and carboplatin in extensive-stage small cell lung cancer. Lung Cancer 2003;40:91-97.
35. Niell HB, Herndon JE, Miller A, et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B trial 9732. J Clin Oncol 2005;23:3752-3759.